Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 2, 2013

Primary Completion Date

June 3, 2016

Study Completion Date

March 19, 2026

Conditions
Grade 3a Follicular LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRefractory Follicular Lymphoma
Interventions
DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (13)

19111

Fox Chase Cancer Center, Philadelphia

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

55416

Metro Minnesota Community Oncology Research Consortium, Saint Louis Park

Park Nicollet Clinic - Saint Louis Park, Saint Louis Park

55905

Mayo Clinic in Rochester, Rochester

63110

Washington University School of Medicine, St Louis

85259

Mayo Clinic in Arizona, Scottsdale

119074

National University Hospital Singapore, Singapore

168583

National Cancer Centre Singapore, Singapore

32224-9980

Mayo Clinic in Florida, Jacksonville

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 2V7

Kingston Health Sciences Centre, Kingston

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH